Get the Stockscreener App
11.44
7.52%
0.80
After Hours:
11.44
Trevi Therapeutics Inc stock is traded at $11.44, with a volume of 1.14M.
It is up +7.52% in the last 24 hours and up +0.70% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
See More
Previous Close:
$10.64
Open:
$10.83
24h Volume:
1.14M
Relative Volume:
0.83
Market Cap:
$1.47B
Revenue:
-
Net Income/Loss:
$-42.76M
P/E Ratio:
-35.66
EPS:
-0.3208
Net Cash Flow:
$-42.09M
1W Performance:
+7.02%
1M Performance:
+0.70%
6M Performance:
+35.22%
1Y Performance:
+73.07%
1-Day Range:
$10.70
$11.74
1-Week Range:
$10.25
$11.74
52-Week Range:
$4.85
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
11.44 | 1.37B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics (NASDAQ:TRVI) Shares Up 9.4%What's Next? - MarketBeat
These analysts revise their forecasts on Trevi Therapeutics following Q4 earnings - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN
Aug Wrap: Will Trevi Therapeutics Inc outperform tech stocks2026 Trading Recap & AI Powered Trade Plan Recommendations - baoquankhu1.vn
TRVI SEC FilingsTrevi Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
TRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Research Analysts Issue Forecasts for TRVI FY2026 Earnings - MarketBeat
Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus
Trading Action: Can Trevi Therapeutics Inc continue delivering strong returnsMarket Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings - Sahm
TRVI: Jones Trading Lowers Price Target While Maintaining Buy Ra - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
What is HC Wainwright's Forecast for TRVI Q1 Earnings? - MarketBeat
Does Trevi Therapeutics (TRVI) have the potential to rally 102.07% as Wall Street analysts expect? - MSN
Trevi Therapeutics Q4 Earnings Call Highlights - MarketBeat
Morgan Stanley Lowers Price Target for Trevi Therapeutics (TRVI) to $18.00 | TRVI Stock News - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley - MarketBeat
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating By Investing.com - Investing.com India
Trevi Therapeutics Chronic Cough Programs: FDA End-of-Phase 2 Meeting & Phase III PlansNews and Statistics - IndexBox
Trevi Therapeutics 2025 Annual Report Highlights: Haduvio Development, Clinical Progress, and Competitive Position - Minichart
Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved - MSN
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Trevi Therapeutics (TRVI) Earnings Transcript - AOL.com
TRVI: Today's Analyst Rating Maintained at Buy with $19 Target | - GuruFocus
Needham raises Trevi Therapeutics stock price target on trial plans By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating - Investing.com
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00 - MarketBeat
Trevi Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected - AlphaStreet
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
TRVI: Needham Raises Price Target to $24.00 and Maintains Buy Ra - GuruFocus
Earnings call transcript: Trevi Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Decoding Trevi Therapeutics Inc (TRVI): A Strategic SWOT Insight - GuruFocus
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Analysis Recap: Is Trevi Therapeutics Inc subject to activist investor interestWeekly Market Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
TRVI: Positive clinical results and strong cash position set up pivotal chronic cough trials and market expansion - TradingView
TRVI: Positive clinical data and robust cash position set stage for pivotal chronic cough trials - TradingView
Earnings call transcript: Trevi Therapeutics Q4 2025 earnings beat expectations - Investing.com
Trevi Therapeutics (TRVI) Advances Chronic Cough Trials with Str - GuruFocus
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates - Bitget
Trevi Therapeutics (NASDAQ:TRVI) Releases Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Trevi Therapeutics, Inc. (hereinafter referred to as "the Company") has recently officially disclosed its financial report for the fourth quarter and full year of 2025, while simultaneously updating the market on the latest business developments. - Bitget
TREVI THERAPEUTICS ($TRVI) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (TRVI) Trevi Therapeutics Posts Q4 Loss $-0.06, vs. FactSet Est of Loss of $-0.10 - marketscreener.com
TRVI: Advanced Haduvio in late-stage trials, but remains pre-revenue and reliant on future funding - TradingView
Trevi Therapeutics 10-K: Net loss $42.8M; loss from operations $49.3M - TradingView
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):